
    
      Phase Ib Patients will be treated with twice-daily dosing of FTD/TPI in a 3+3 dose escalation
      design Phase II

      Oral FTD/TPI at RP2D will be administered until disease progression, intolerable toxicity or
      patient withdrawal.

      2 parallel cohorts of patients will be enrolled : Cohort A : patients with prior exposure to
      fluoropyrimidines Cohort B : patients without prior exposure to fluoropyrimidines
    
  